10 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd
4 Mar 24
Regulation FD Disclosure
7:00am
and long-term growth of JELMYTO revenue; expected revenue trends forJELMYTO; UroGen’s pipeline supporting long-term sustainable growth; the potential … Sustainable Growth JELMYTO UGN-102 UGN-301 (UGN-101) Phase 3 Phase 1 ~6K – 7K ~18,700 ~82,000 1 addressable U.S. population addressable U.S. population
8-K
EX-99.1
URGN
UroGen Pharma Ltd
7 Feb 24
Regulation FD Disclosure
4:15pm
and long-term growth of JELMYTO revenue; expected revenue trends forJELMYTO; UroGen’s pipeline supporting long-term sustainable growth; the potential … . Leverages physiologic flow of urine to provide natural exit from the body
Unlocking A Strong Foundational Pipeline Supporting Long-Term Sustainable
10-K/A
2022 FY
URGN
UroGen Pharma Ltd
1 May 23
Annual report (amended)
4:37pm
priorities, and build towards creation of long-term, sustainable shareholder value.
Our 2022 corporate performance highlights include:
Achieved year
8-K
EX-99.1
j4e2iuk
11 Jan 21
Regulation FD Disclosure
8:31am
8-K
EX-99.1
vxfierdf
12 Nov 19
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent
8:06am
8-K
EX-99.2
cc2a4ed6nyrxvezu7sd
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
8-K
EX-99.1
yntja
9 May 19
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent
8:12am
- Prev
- 1
- Next